United Therapeutics Corporation

Undervalued United Therapeutics Corporation (UTHR)

One of the cheapest stocks in our All Investable Stock Screener is United Therapeutics Corporation (NASDAQ: UTHR).

Q1 hedge fund letters, conference, scoops etc, Also read Lear Capital: Financial Products You Should Avoid?

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The firm is a market leader in two of the three primary drugs classes used to treat PAH. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug.

A quick look at United Therapeutics share price history over the past twelve months shows that the price is down 12.5%, but here’s why the company remains undervalued.

United Therapeutics Corporation

(Source: Morningstar)

The following data is from the company’s latest financial statements, dated March 2018.

The company’s latest balance sheet shows that United Therapeutics has $1.257 Billion in total cash and cash equivalents. Further down the balance sheet we can see that the company has $250 Million in total debt. Therefore, United Therapeutics has a net cash position of $1.007 Billion (cash minus debt).

If we consider that United Therapeutics currently has a market cap of $4.706 Billion, when we subtract the net cash totaling $1.007 Billion that equates to an Enterprise Value of $3.699 Billion.

If we move over to the company’s latest income statements we can see that United Therapeutics has $1.079 Billion* in trailing twelve month operating earnings which means that the company is currently trading on an Acquirer’s Multiple of 3.42, or 3.42 times operating earnings. That places United Therapeutics squarely in undervalued territory.

The Acquirer’s Multiple is defined as:

Enterprise Value/Operating Earnings*

*We make adjustments to operating earnings by constructing an operating earnings figure from the top of the income statement down, where EBIT and EBITDA are constructed from the bottom up. Calculating operating earnings from the top down standardizes the metric, making a comparison across companies, industries and sectors possible, and, by excluding special items–income that a company does not expect to recur in future years–ensures that these earnings are related only to operations.

It’s also important to note that if we take a look at the company’s latest cash flow statements we can see that United Therapeutics generated trailing twelve month operating cash flow of $519 Million and had $108 Million in Capex. That equates to $411 Million in trailing twelve month free cash flow, or a FCF/EV Yield of 11%.

In terms of United Therapeutics’ annualized Return on Equity (ROE) for the quarter ending March 2018. A quick calculation shows that the company had $2.102 Billion in equity for the quarter ending December 2017 and $2.369 Billion for the quarter ending March 2018. If we divide that number by two we get $2.235 Billion. If we consider that the company has $484 Million (ttm) in net income, that equates to an annualized Return on Equity (ROE) for the quarter ending March 2018 of 22%.

Summary

In summary, United Therapeutics is trading on a P/E of 9.8, which is considerably lower than its 5Y average of 18.6**, and an Acquirer’s Multiple of 3.42, or 3.42 times operating earnings. The company has a strong balance sheet, with a net cash position of $1.007 Billion and a cash-debt ratio of 5x. United Therapeutics has a FCF/EV Yield of 11% (ttm) and an annualized Return on Equity (ROE) for the quarter ending March 2018 of 22% (ttm). All of which indicates that the company remains undervalued.

(**Source: Morningstar)

More About The All Investable Stock Screener (CAGR 25%)

From January 2, 1999 to November 29, 2017, the All Investable Stock Screener generated a total return of 6,765 percent, or a compound growth rate (CAGR) of 25.0 percent per year. This compared favorably with the Russell 3000 TR, which returned a cumulative total of 321 percent, or 6.4 percent compound.

For more articles like this, check out our recent articles here.

Article by The Acquirer’s Multiple

LEAVE A COMMENT


Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Congrats! Are you a smart person?

We have an exclusive targeted for being a sophisticated and loyal reader.

Welcome in the new year by signing up up for ValueWalkPremium today and get our exclusive content for 40% off. This is our second biggest discount ever!!

Use coupon code VIP20 or click on the button below

Limited time offer only ENDS 1/31/2019 or after next 30 23 subscribers take advantage whichever comes first – please do not share this discount with others

 

0